CRISPR Therapeutics AG
Company Profile
Business description
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Contact
Baarerstrasse 14
ZugCH-6300
CHET: +41 415613277
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
407
CRISPR Therapeutics AG News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,634.60 | 67.60 | 0.79% |
CAC 40 | 7,213.32 | 14.87 | 0.21% |
DAX 40 | 19,146.17 | 141.39 | 0.74% |
Dow JONES (US) | 43,870.35 | 461.88 | 1.06% |
FTSE 100 | 8,149.27 | 64.20 | 0.79% |
HKSE | 19,601.11 | 103.90 | -0.53% |
NASDAQ | 18,972.42 | 6.28 | 0.03% |
Nikkei 225 | 38,187.05 | 160.88 | 0.42% |
NZX 50 Index | 12,918.97 | 153.73 | 1.20% |
S&P 500 | 5,948.71 | 31.60 | 0.53% |
S&P/ASX 200 | 8,391.50 | 68.50 | 0.82% |